SEP 22, 2015 09:00 AM PDT

WEBINAR: Galectin-3 A Step Towards a Clearer Pathway in Heart Failure Management

SPONSORED BY: Abbott Molecular, Abbott Molecular
  • Vice Chief of Medicine, Baylor University Medical Center , and Principal Faculty in internal medicine, Texas A & M University Health Sciences Center
      After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough is Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX and is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications including the "Interface between Renal Disease and Cardiovascular Illness" in Braunwald's Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine, associated editor of the American Journal of Cardiology, and serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.

    DATE: Sept 22, 2015
    TIME: 9:00am PDT, 12:00PM EDT

    Heart failure is a complex syndrome and affects over 5.1 Million Americans today with approximately 500,000 new heart failure cases each year. Heart failure is the leading cause of emergency room visits, hospitalizations, and death for Americans today. Although, there have been significant advances in heart failure diagnosis, management, and treatment there is still a need for new tools to help optimize the management of this healthcare burden. Recently, novel biomarkers have emerged as additional tools to aid in prognosis and management of heart failure. During today's webcast, we will learn about a new and emerging biomarker called galectin-3 and how it can be used as a management tool for heart failure patients in the US.

    Learning Objectives:
    • Understand what is galectin-3
    • Learn about pathophysiology of cardiac fibrosis and the role of galectin-3
    • Comprehend how galectin-3 can used as a management tool for heart failure patients

    Who Should Attend:
    • Laboratorians
    • Heart failure nurses
    • Heart failure specialists
    • Cardiologists
    • Emergency Physicians

    Show Resources
    Loading Comments...